Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
  • Patent number: 8815836
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: August 26, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cueva Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20140235713
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 21, 2014
    Applicants: The Hospital for Sick Children, McMaster University
    Inventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
  • Publication number: 20140234343
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.
    Type: Application
    Filed: November 12, 2012
    Publication date: August 21, 2014
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Publication number: 20140228430
    Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.
    Type: Application
    Filed: January 16, 2014
    Publication date: August 14, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: Daniel A. Gamache, Mark R. Hellberg, Peter G. Klimko, Kerry L. Markwardt, John M. Yanni, Eric C. Carlson
  • Publication number: 20140228434
    Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: UCB PHARMA GMBH
    Inventor: Claus MEESE
  • Patent number: 8802729
    Abstract: Biodegradable detergent compositions comprising enzymes and 1,3-propanediol are provided. The 1,3-propanediol in the composition is biologically derived and enhances the stability of the enzymes in the composition. The compositions also exhibit a low anthropogenic CO2 emission profile.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 12, 2014
    Assignee: DuPont Tate & Lyle Bio Products Company, LLC
    Inventors: Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
  • Publication number: 20140220164
    Abstract: Compositions useful for controlling pests are disclosed. In some embodiments, the composition includes a pesticidal natural oil and a polar aromatic solvent or an alkyl alcohol solvent. Methods of making and using the compositions are disclosed.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 7, 2014
    Applicant: 0903608 B.C. Ltd.
    Inventors: Karan MANHAS, Annett ROZEK
  • Publication number: 20140220158
    Abstract: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a method of rejuvenating skin affected by intrinsic aging and/or photo-induced aging comprising topically applying a topical formulation to the skin, wherein said topical formulation is comprised of ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, carnosic acid, ?-tocopherol, 0.01 weight percent to 20 weight percent of a mixture of ethyl lactate and isoamyl lactate, wherein the weight ratio of the ethyl lactate to the isoamyl lactate is within the range of 1:10 to 20:1, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: AD LUNAM LABS INC.
    Inventors: William H. Beeson, Alvin T. Rockhill
  • Patent number: 8796332
    Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: August 5, 2014
    Assignee: Regents of the University of Minnesota
    Inventors: Patrick M. Schlievert, Marnie L. Peterson
  • Publication number: 20140213647
    Abstract: The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome.
    Type: Application
    Filed: May 16, 2012
    Publication date: July 31, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Won suk Sun, Hyo Jin Jeon, Dongsun Min, Woongsik Kim, Taeksu Kim, Do-Seung Kum, Keun-Ho Ryu, Hae-In Rhee, Yang Hae Park, Hyun-Joo Son, Eun-ju Park, Bong-yong Lee, Hojin Namgung, Minseok Park, Minseok Kang
  • Publication number: 20140200256
    Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: SIGNATURE R&D HOLDINGS, LLC
    Inventor: V. Ravi Chandran
  • Publication number: 20140199401
    Abstract: A stable extend release pharmaceutical composition is disclosed.
    Type: Application
    Filed: July 4, 2012
    Publication date: July 17, 2014
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Ajay Kumar Handa, Ketan Tulsidas Savjani
  • Publication number: 20140194509
    Abstract: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.
    Type: Application
    Filed: December 10, 2013
    Publication date: July 10, 2014
    Applicants: Government of the USA, as Represented by the Secretary, Department of Health and Human Services, Isis Innovation Limited
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Patent number: 8772340
    Abstract: A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 8, 2014
    Assignee: Dipharma Francis S.r.l.
    Inventors: Marco Artico, Emanuele Attolino, Pietro Allegrini, Gabriele Razzetti
  • Publication number: 20140187617
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Patent number: 8758743
    Abstract: A coenzyme Q10-containing composition comprising a coenzyme Q10 and a hydrophilic fatty acid ester of a polyhydric alcohol; a coenzyme Q10-containing composition comprising a coenzyme Q10, a lipophilic fatty acid ester of a polyhydric alcohol and a hydrophilic fatty acid ester of a polyhydric alcohol; and a food or beverage comprising the coenzyme Q10-containing composition as defined above.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: June 24, 2014
    Assignee: Taiyo Kagaku Co., Ltd.
    Inventors: Rumi Yamaguchi, Hiroaki Yamaguchi, Hironobu Nanbu, Lekh Raj Juneja, Nagahiro Yamazaki
  • Patent number: 8759354
    Abstract: Disclosed is a pharmaceutical composition comprising a pyrazine derivative represented by the general formula: [wherein R1 and R2 independently represent a hydrogen atom or a halogen atom; and R3 represents a hydrogen atom or an amino-protecting group] or a salt thereof and at least one neuraminidase inhibitor. The pharmaceutical composition is useful for a treatment including the treatment or prevention of influenza. Also disclosed is a method of using these components in combination. The method is useful for a treatment including the treatment or prevention of influenza.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: June 24, 2014
    Assignee: Toyama Chemical Co., Ltd.
    Inventor: Masako Maekawa
  • Publication number: 20140171490
    Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.
    Type: Application
    Filed: August 9, 2013
    Publication date: June 19, 2014
    Applicant: PHARMALINGT INC.
    Inventors: Yossi Gross, Rafi Herzog, Steven B. Koevary
  • Publication number: 20140163099
    Abstract: The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Kenya ISHIDA, Tomoko YAMAMOTO, Miho SUZUKI
  • Publication number: 20140155457
    Abstract: Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (PEG) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease.
    Type: Application
    Filed: October 4, 2013
    Publication date: June 5, 2014
    Inventors: KWANG NHO, Min Jung AHN, Byung Hee SOHN, Chang Min HYUN, Jung Hun LEE
  • Patent number: 8729123
    Abstract: The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt % docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: May 20, 2014
    Assignee: N.V. Nutricia
    Inventors: Bernd Stahl, Gunther Boehm, Christopher Beermann, Johan Garssen
  • Patent number: 8728978
    Abstract: Suggested are biocide compositions, comprising (a) esters based on ketocarboxylic acids, (b) biocides, and optionally (c) oil components or co-solvents and/or (d) emulsifiers. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. over a longer period.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 20, 2014
    Assignee: Cognis IP Management GmbH
    Inventors: Joaquin Bigorra Llosas, Stéphanie Merlet, Ramon Valls, Stefan Busch
  • Patent number: 8716338
    Abstract: The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: May 6, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Christopher Young
  • Publication number: 20140121173
    Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
    Type: Application
    Filed: August 2, 2013
    Publication date: May 1, 2014
    Applicant: Run Them Sweet, LLC
    Inventors: Michael A. Horning, George A. Brooks
  • Patent number: 8703829
    Abstract: The invention provides compounds of Formula (I): R1?R2??(I) wherein R1 and R2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: April 22, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Gerald B. Hammond, Bo Xu, Paula J. Bates
  • Publication number: 20140106005
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.
    Type: Application
    Filed: January 18, 2013
    Publication date: April 17, 2014
    Applicant: Biosuccess Biotech Co., Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20140105952
    Abstract: Compositions and methods for controlling and/or repelling bedbugs are provided. The compositions comprise one or more compounds having bedbug repellant activity. Such compounds may be, for example, naturally occurring semiochemicals or structural or functional analogs of naturally occurring semiochemicals. Exemplary compounds are compounds of general formula (I).
    Type: Application
    Filed: March 29, 2012
    Publication date: April 17, 2014
    Applicant: SemiosBIO Technologies Inc.
    Inventor: Michael Gilbert
  • Publication number: 20140105843
    Abstract: The present invention relates to a process for the preparation of an ester comprising an after-treatment of the ester to give an ester in granule form of defined particle size distribution, a device for carrying out this process, a process for the preparation of a thermoplastic composition comprising the ester prepared according to the invention, a process for the production of a shaped article comprising the ester according to the invention or the thermoplastic composition according to the invention, a process for the production of a packed product, a process for the production of an at least partly coated object, and uses of the esters according to the invention as an additive in various compositions.
    Type: Application
    Filed: February 21, 2012
    Publication date: April 17, 2014
    Inventors: Peter Daute, Wilhelm Reiners, Martin Schäfer, Udo Frerichs, Hinrich Hildebrandt, Joern Ellerbrake
  • Publication number: 20140107196
    Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
    Type: Application
    Filed: March 13, 2013
    Publication date: April 17, 2014
    Applicant: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventor: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
  • Publication number: 20140099364
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: October 7, 2005
    Publication date: April 10, 2014
    Applicant: Forward Pharma A/S
    Inventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
  • Publication number: 20140086879
    Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.
    Type: Application
    Filed: September 23, 2013
    Publication date: March 27, 2014
    Applicant: Marrone Bio Innovations, Inc.
    Inventors: Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing, Sarah Lewis
  • Publication number: 20140086878
    Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 27, 2014
    Applicant: MARRONE BIO INNOVATIONS, INC
    Inventors: Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing
  • Publication number: 20140088185
    Abstract: A buccally administered dosage for assisting with the relief of common digestive complaints where the dosage formed into a hard candy dosage drop, where the dosage is a sugar base infused with a botanical derivative that has concentrated active compositions in sufficient concentration to provide a soothing effect of digestive upset, and where the drop has favorable organoleptic properties.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Inventors: Dustin Garth James, Helen Kim-James
  • Patent number: 8680051
    Abstract: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: March 25, 2014
    Inventors: Qinghua Wang, Soltani Nepton
  • Patent number: 8673819
    Abstract: The present invention teaches a surfactant blend composition of at least one nonionic alkoxylate and at least one sugar-based surfactant, and its use as an adjuvant for pesticides. The pesticidal composition employing the surfactant blend composition of the invention realizes an efficacy that is unexpectedly superior to similar pesticidal compositions which employ only the individual surfactant components. The composition of the present invention is useful as a tank side additive, or as a component in herbicidal formulations. In addition the compositions of the present invention are useful as adjuvants for other pesticides, such as, fungicides, insecticides, plant growth regulators, acaracides and the like.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: March 18, 2014
    Assignee: Akzo Nobel N.V.
    Inventor: Jinxia Susan Sun
  • Publication number: 20140073693
    Abstract: The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and A?-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 13, 2014
    Applicants: SAVIND, INC., UNIVERSITY OF SOUTH FLORIDA
    Inventors: Dominic Paul D'Agostino, Jay B. Dean, Raffaele Pilla, Patrick Arnold
  • Patent number: 8669261
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 11, 2014
    Assignee: Congenia SLR
    Inventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • Publication number: 20140066500
    Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan BHAT, Seema BHAT
  • Publication number: 20140045938
    Abstract: Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Irina Budunova, Alexander Yemelyanov
  • Patent number: 8642654
    Abstract: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: February 4, 2014
    Assignees: ISIS Innovation Limited, Government of the USA, as Represented by the Sec-Retary, Department of Health and Human Services
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Patent number: 8642650
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: February 4, 2014
    Assignee: Zafgen, Inc.
    Inventors: Thomas E. Hughes, James E. Vath
  • Publication number: 20140031425
    Abstract: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable.
    Type: Application
    Filed: October 1, 2013
    Publication date: January 30, 2014
    Inventor: John Alex Lopes
  • Patent number: 8637570
    Abstract: A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 28, 2014
    Assignee: Ferring International Center S.A.
    Inventors: Klaus Jensen, Soren Halskov, Henning Lund
  • Publication number: 20140024709
    Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 23, 2014
    Applicant: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan BHAT, Kouacou ADIEY
  • Publication number: 20140018330
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 16, 2014
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20140011873
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
    Type: Application
    Filed: September 13, 2013
    Publication date: January 9, 2014
    Applicant: BIOSUCCESS BIOTECH CO., LTD
    Inventors: Zheng Tao HAN, Hung-Fong CHEN
  • Publication number: 20130345269
    Abstract: Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.
    Type: Application
    Filed: November 3, 2011
    Publication date: December 26, 2013
    Inventors: Ragnar Hovland, Tore Skjæret, David Fraser
  • Publication number: 20130345171
    Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.
    Type: Application
    Filed: June 11, 2013
    Publication date: December 26, 2013
    Inventors: Stanley L. Hazen, Bruce Levison, Zeneng Wang
  • Publication number: 20130336916
    Abstract: The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C5H8)n, and its derivatives and analogs thereof, as active insecticidal ingredients; certain botanical essential oils as synergists, and other select ingredients as additives.
    Type: Application
    Filed: June 18, 2012
    Publication date: December 19, 2013
    Inventor: Tao Zhong
  • Publication number: 20130338224
    Abstract: The invention concerns a decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, comprising as active components eugenol, eugenol acetate, vanillin and carvacrol, characterized in that said active constituents are present in the following percentages by weight: at least about 12% eugenol, at least about 3% eugenol acetate, at least about 0.1% vanillin and at least about 0.5% carvacrol. Said decontaminating composition can be used as liquid or solid soaps. It can also impregnate in liquid form fabrics and nonwoven fabrics such as garments for medical use, bed sheets, slip covers, surgery drape, dressings and gauze such as those applied to the skin of serious burn victims.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 19, 2013
    Applicant: HIGHTECH BIO-ACTIVITIES HOLDING GMBH
    Inventors: Hakima BELBACHIR, Jean ANGELIDIS